Clinical trial registry record

Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 22, 2019.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01791088
Last registry update
April 22, 2019
Status
Completed
Phase
Phase 1
Sponsor
University of Chicago
Enrollment
56
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
56
Population
ALL · 12 Years
Duration
2012-06-13 to 2018-08-17
Intervention
sirolimus; pharmacological study; laboratory biomarker analysis
Comparator
Not reported
Outcomes measured
Change in fasting glucose and fasting triglycerides — Baseline to 8 days; Change in fasting glucose and fasting triglycerides — Baseline to 15 days; Change in fasting glucose and fasting triglycerides — Baseline to 29 days; Association between genetic variants and changes in fasting glucose and triglycerides — Up to 12 months; Change in tumor size assessed using RECIST — Up to 2 years; Correlation of toxicities graded using CTCAE version 4.0 with glucose/triglyceride changes — Up to 2 years; Regulatory T cells (Tregs) — Baseline to 28 days
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON